http://www.reuters.com/article/pressRelease/idUS169794+20-May-2009+PRN20090520
The data were presented today by Saibal Kar, M.D., director of interventional
cardiac research at Cedars-Sinai Medical Center and the lead enrolling
investigator of the EVEREST trials.
"The High Risk Registry data support our belief that the MitraClip therapy is
a safe and clinically beneficial treatment alternative for select patients
suffering from significant functional or degenerative MR," said Dr. Kar.
"Patients otherwise unable to withstand more invasive treatments can benefit
from the MitraClip therapy while avoiding the risk of increased morbidity and
mortality often associated with surgical treatment."